Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Melanoma Res. 2013 Apr;23(2):175-8. doi: 10.1097/CMR.0b013e32835e589c.
We present a patient with metastatic BRAF-mutated melanoma who achieved long-term stabilization of leptomeningeal disease (LMD) with sequential whole-brain radiation therapy and vemurafenib. A 53-year-old woman with melanoma that harbored the BRAF V600E mutation and had that metastasized to multiple lymph nodes, lungs, breast, and subcutaneous tissue had developed symptomatic LMD 16 months after starting vemurafenib treatment despite achieving a substantial response at the existing metastatic sites. Vemurafenib was discontinued for 7 days, she received whole-brain radiation therapy (30 Gy in 10 fractions), and 7 days after completing the radiation therapy, she resumed vemurafenib therapy. The neurologic symptoms improved significantly, and a cerebrospinal fluid examination revealed disappearance of melanoma cells. She remained alive with radiologically stable LMD for at least 18 months after the whole-brain radiation therapy.
我们报告了一例转移性 BRAF 突变型黑色素瘤患者,其通过序贯全脑放疗和 vemurafenib 治疗实现了脑脊髓疾病(LMD)的长期稳定。一位 53 岁女性患有黑色素瘤,携带 BRAF V600E 突变,已转移至多个淋巴结、肺部、乳房和皮下组织,尽管在现有转移性部位取得了显著反应,但在开始 vemurafenib 治疗 16 个月后出现了症状性 LMD。vemurafenib 停药 7 天,她接受了全脑放疗(30 Gy 分 10 次),放疗完成后 7 天,她恢复了 vemurafenib 治疗。神经系统症状显著改善,脑脊液检查显示黑色素瘤细胞消失。全脑放疗后至少 18 个月,她仍然存活且 LMD 影像学稳定。